Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report

Raches Ella; Siddharth Reddy; Harsh Jogdand; Vamshi Sarangi; Brunda Ganneru; Sai Prasad; Dipankar Das; Dugyala Raju; Usha Praturi; Gajanan Sapkal; Pragya Yadav; Prabhakar Reddy; Savita Verma; Chandramani Singh; Sagar Vivek Redkar; Chandra Sekhar Gillurkar; Jitendra Singh Kushwaha; Satyajit Mohapatra; Amit Bhate; Sanjay Rai; Samiran Panda; Priya Abraham; Nivedita Gupta; Krishna Ella; Balram Bhargava; Krishna Mohan Vadrevu

bioRxiv (2020) - Comments
doi: 10.1101/2020.12.21.20248643

Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, Dipankar Das, Dugyala Raju, Usha Praturi, Gajanan Sapkal, Pragya Yadav, Prabhakar Reddy, Savita Verma, Chandramani Singh, Sagar Vivek Redkar, Chandra Sekhar Gillurkar, Jitendra Singh Kushwaha, Satyajit Mohapatra, Amit Bhate, Sanjay Rai